医疗技术公司Glaukos(GKOS)今日盘中大跌13.2%,引发市场广泛关注。
该公司昨日公布了2024年第四季度财报,数据显示当季净亏损达到2220万美元,大幅超出市场预期的2080万美元亏损。尽管营收达到1.055亿美元高于预期,但亏损扩大的情况仍令投资者信心受挫。
值得一提的是,Glaukos的主要产品iStent inject W是一种用于治疗青光眼的创新医疗器械,针对这种常见但损害视神经的眼病。公司的这一核心业务前景广阔,但本季度的财报业绩不佳或许给市场带来一些负面影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.